Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes

Journal of Diabetes and its Complications

Volumn 21, Issue 3, 2007, Pages 166-171

  Pollex, Rebecca L ^a   Mamakeesick, Mary ^b   Zinman, Bernard ^c   Harris, Stewart B ^d   Hegele, Robert A ^a   Hanley, Anthony J G ^c  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b Sandy Lake Health and Diabetes Project   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Genetics; Nephropathy; Polymorphism; PPARG; Type 2 diabetes

Indexed keywords

ALBUMIN; CREATININE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ABORIGINE; ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; HETEROZYGOTE DETECTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

AGE OF ONSET; ALANINE; AMINO ACID SUBSTITUTION; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DNA PRIMERS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDIANS, NORTH AMERICAN; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; ONTARIO; PPAR GAMMA; PROLINE;

EID: 34247570371     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2006.02.006     Document Type: Article

References (23)

1. Al-Shali K.Z., House A.A., Hanley A.J., Khan H.M., Harris S.B., Zinman B., Mamakeesick M., Fenster A., Spence J.D., and Hegele R.A. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke 35 (2004) 2036-2040
2. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., Lane C.R., Schaffner S.F., Bolk S., Brewer C., Tuomi T., Gaudet D., Hudson T.J., Daly M., Groop L., and Lander E.S. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics 26 (2000) 76-80
3. Argmann C.A., Cock T.A., and Auwerx J. Peroxisome proliferator-activated receptor gamma: The more the merrier?. European Journal of Clinical Investigation 35 (2005) 82-92 (discussion, 80)
4. Caramori M.L., Canani L.H., Costa L.A., and Gross J.L. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 52 (2003) 3010-3013
5. Deeb S.S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., Laakso M., Fujimoto W., and Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics 20 (1998) 284-287
6. Desvergne B., Michalik L., and Wahli W. Be fit or be sick: Peroxisome proliferator-activated receptors are down the road. Molecular Endocrinology 18 (2004) 1321-1332
7. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S., Vidal-Puig A., Flier J., Briggs M.R., Staels B., Vidal H., and Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. Journal of Biological Chemistry 272 (1997) 18779-18789
8. Hanley A.J., Harris S.B., Mamakeesick M., Goodwin K., Fiddler E., Hegele R.A., Spence J.D., House A.A., Brown E., Schoales B., McLaughlin J.R., Klein R., and Zinman B. Complications of type 2 diabetes among aboriginal Canadians: Prevalence and associated risk factors. Diabetes Care 28 (2005) 2054-2057
9. Hanley A.J.G., Harris S.B., Barnie A., Gittelsohn J., Wolever T.M.S., Logan A., and Zinman B. The Sandy Lake Health and Diabetes Project: Design, methods and lessons learned. Chronic Diseases in Canada 16 (1995) 149-156
10. Hanley A.J.G., Harris S.B., Mamakeesick M., Goodwin K., Fiddler E., Hegele R.A., McLaughlin J.R., and Zinman B. Complications of type 2 diabetes among Native Canadians: Increasing our understanding of prevalence and risk factors. Canadian Journal of Diabetes 27 (2003) 455-463
11. Harris S.B., Gittelsohn J., Hanley A., Barnie A., Wolever T.M., Gao J., Logan A., and Zinman B. The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care 20 (1997) 185-187
12. Hegele R.A., Cao H., Harris S.B., Zinman B., Hanley A.J., and Anderson C.M. Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. Journal of Clinical Endocrinology and Metabolism 85 (2000) 2014-2019
13. Herrmann S.M., Ringel J., Wang J.G., Staessen J.A., and Brand E. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 51 (2002) 2653-2657
14. Masugi J., Tamori Y., Mori H., Koike T., and Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochemical and Biophysical Research Communications 268 (2000) 178-182
15. Meltzer S., Leiter L., Daneman D., Gerstein H.C., Lau D., Ludwig S., Yale J.F., Zinman B., and Lillie D. 1998 Clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. Canadian Medical Association Journal 159 Suppl 8 (1998) S1-S29
16. Parsons M.P., Newman D.J., Newall R.G., and Price C.P. Validation of a point-of-care assay for the urinary albumin:creatinine ratio. Clinical Chemistry 45 (1999) 414-417
17. Poulsen P., Andersen G., Fenger M., Hansen T., Echwald S.M., Volund A., Beck-Nielsen H., Pedersen O., and Vaag A. Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: Thrifty genotype, thrifty phenotype or both?. Diabetes 52 (2003) 194-198
18. Ridker P.M., Cook N.R., Cheng S., Erlich H.A., Lindpaintner K., Plutzky J., and Zee R.Y. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arteriosclerosis, Thrombosis, and Vascular Biology 23 (2003) 859-863
19. Stumvoll M., and Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51 (2002) 2341-2347
20. USRDS. U.S. Renal Data System 2004 annual data report: Atlas of end-stage renal disease in the United States (2004), National Institutes of Health, Bethesda, MD
21. Wilson R., Krefting L.H., Sutcliffe P., and VanBussel L. Incidence and prevalence of end-stage renal disease among Ontario's James Bay Cree. Canadian Journal of Public Health 83 (1992) 143-146
22. Young T.K., Kaufert J.M., McKenzie J.K., Hawkins A., and O'Neil J. Excessive burden of end-state renal disease among Canadian Indians: A national survey. American Journal of Public Health 79 (1989) 756-758
23. Young T.K., Reading J., Elias B., and O'Neil J.D. Type 2 diabetes mellitus in Canada's first nations: Status of an epidemic in progress. Canadian Medical Association Journal 163 (2000) 561-566